Phathom Pharmaceuticals, Inc. short interest in 2026
In 2026, Phathom Pharmaceuticals, Inc.'s disclosed short interest ran from 14.79% of shares outstanding on 15 Jan 2026 to 12.56% on 15 Sep 2026, a change of -2.23 percentage points. The year's high was 16.47% on 13 Feb 2026 and its low 12.21% on 30 Apr 2026, averaging 14.53% across 17 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 14.85 days on 13 Feb 2026. Full history: Phathom Pharmaceuticals, Inc..
Cite this page
By year: 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2026 in figures
- Start of year
- 14.79% (15 Jan 2026)
- End of year
- 12.56% (15 Sep 2026)
- Change
- -2.23 pp
- High
- 16.47% (13 Feb 2026)
- Low
- 12.21% (30 Apr 2026)
- Average
- 14.53%
- Highest days to cover
- 14.85 (13 Feb 2026)
- SEC filings marked
- 7
Every report in 2026
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 15 Jan 2026 | 14.79% | 6.48 | results (8-K) |
| 30 Jan 2026 | 16.02% | 10.88 | |
| 13 Feb 2026 | 16.47% | 14.85 | |
| 27 Feb 2026 | 15.70% | 9.81 | 10-K filed, results (8-K) |
| 13 Mar 2026 | 16.39% | 10.93 | |
| 31 Mar 2026 | 14.95% | 9.23 | |
| 15 Apr 2026 | 13.36% | 9.92 | |
| 30 Apr 2026 | 12.21% | 5.88 | 10-Q filed, results (8-K) |
| 15 May 2026 | 12.90% | 8.68 | |
| 29 May 2026 | 12.98% | 9.41 | |
| 15 Jun 2026 | 14.00% | 10.36 | |
| 30 Jun 2026 | 15.04% | 11.67 | |
| 15 Jul 2026 | 15.20% | 9.00 | |
| 31 Jul 2026 | 16.47% | 8.70 | 10-Q filed, results (8-K) |
| 14 Aug 2026 | 14.55% | 6.87 | |
| 31 Aug 2026 | 13.38% | 11.01 | |
| 15 Sep 2026 | 12.56% | 9.11 |
See also: Phathom Pharmaceuticals, Inc.'s full history · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.